Concomitant use of Tyrosine-Kinase Inhibitor and Mepolizumab in Asthma Secondary to Chronic Myeloid Leukemia with Hypereosinophilia

Antiinflamm Antiallergy Agents Med Chem. 2021;20(4):389-393. doi: 10.2174/1871523020999210820091109.

Abstract

Introduction: Asthma and hypereosinophilia have been treated with different therapeutics in the past. Some of them appear to be more effective in symptoms resolution and decreasing eosinophilic count.

Case presentation: We report here an unusual case of asthma with hypereosinophilia secondary to Chronic Myeloid Leukemia (CML) with high prevalence of eosinophilic infiltrate, treated simultaneously with an anti-IL-5 antibody (Mepolizumab) and Tyrosine-kinase Inhibitors (TKI: Imatinib and Bosutinib) for three years. The patient showed a promising reduction of pulmonary exacerbations and good control of CML without developing side effects.

Conclusion: We hope that this finding could inspire further studies on the efficacy and safety of the concomitant use of anti-IL-5 and TKI.

Keywords: Asthma; chronic myeloid leukemia (CML); eosinophilic count.; hypereosinophilia (HE); mepolizumab; tyrosine kinase inhibitors (TKI).

Publication types

  • Case Reports

MeSH terms

  • Anti-Asthmatic Agents / administration & dosage*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Asthma / drug therapy*
  • Asthma / etiology
  • Eosinophils / drug effects*
  • Female
  • Humans
  • Hypereosinophilic Syndrome
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Middle Aged
  • Protein Kinase Inhibitors / therapeutic use*
  • Treatment Outcome
  • Tyrosine

Substances

  • Anti-Asthmatic Agents
  • Antibodies, Monoclonal, Humanized
  • Protein Kinase Inhibitors
  • Tyrosine
  • mepolizumab